Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting
14 März 2023 - 9:53PM
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on
creating and delivering engineered cells as medicines, today
announced that four abstracts, including a late-breaking
abstract, highlighting preclinical data from both the hypoimmune
and fusogen platforms have been accepted for poster presentation at
the 2023 American Association for Cancer Research (AACR) Annual
Meeting taking place April 14-19, 2023 in Orlando, FL.
Late-breaking poster details:
Title: |
Increased potency of CD8-targeted fusosomes enhances CAR gene
delivery to resting primary T cells |
Session
Title: |
Late-Breaking Research:
Experimental and Molecular Therapeutics 3 |
Session
Date: |
Wednesday, April 19, 2023 |
Session
Time: |
9:00 a.m. - 12:30 p.m. ET |
Location: |
Poster Section 35 |
Abstract
Number: |
LB311 |
Poster details:
Title: |
Modulation of resting T cell status to enhance transduction and CAR
T expansion following exposure to CD8-targeted fusosomes |
Session
Category: |
Experimental and Molecular
Therapeutics |
Session
Title: |
Gene and Vector-based
Therapy |
Session
Date: |
Monday, April 17, 2023 |
Session
Time: |
1:30 p.m. - 5:00 p.m. ET |
Location: |
Poster Section 16 |
Abstract
Number: |
2734 |
Title: |
Development of a novel, fully human anti-CD19 chimeric antigen
receptor for in vivo delivery via CD8-targeted fusosome |
Session
Category: |
Experimental and Molecular
Therapeutics |
Session
Title: |
Gene and Vector-based
Therapy |
Session
Date: |
Monday, April 17, 2023 |
Session
Time: |
1:30 p.m. - 5:00 p.m. ET |
Location: |
Poster Section 16 |
Abstract
Number: |
2735 |
Title: |
Engineered hypoimmune CAR T cells provide lasting tumor control in
immunocompetent allogeneic humanized mice even with
re-challenge |
Session
Category: |
Immunology |
Session
Title: |
CAR T-cell Therapy 2 |
Session
Date: |
Tuesday, April 18, 2023 |
Session
Time: |
9:00 a.m. - 12:30 p.m. ET |
Location: |
Poster Section 23 |
Abstract
Number: |
4091 |
Full regular abstracts and late-breaking abstract titles are
available for viewing via the AACR Online Itinerary Planner located
here: https://www.abstractsonline.com/pp8/#!/10828. Late-breaking
abstract text will be posted to the AACR Online Itinerary Planner
and Meeting App on Friday, April 14, 2023 at 12:00 p.m. ET.
About Sana BiotechnologySana Biotechnology,
Inc. is focused on creating and delivering engineered cells as
medicines for patients. We share a vision of repairing and
controlling genes, replacing missing or damaged cells, and making
our therapies broadly available to patients. We are a passionate
group of people working together to create an enduring company that
changes how the world treats disease. Sana has operations in
Seattle, Cambridge, South San Francisco, and Rochester. For more
information about Sana Biotechnology, please visit
https://sana.com/.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements about Sana Biotechnology, Inc. (the “Company,” “we,”
“us,” or “our”) within the meaning of the federal securities laws,
including those related to the Company’s vision, progress, and
business plans; expectations for the Company’s participation at the
2023 American Association for Cancer Research Annual Meeting;
expectations for the Company’s presentations at such meeting,
including the content of such presentations; and expectations for
the publication of abstracts. All statements other than statements
of historical facts contained in this press release, including,
among others, statements regarding the Company’s strategy,
expectations, cash runway and future financial condition, future
operations, and prospects, are forward-looking statements. In some
cases, you can identify forward-looking statements by terminology
such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,”
“continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,”
“intend,” “may,” “objective,” “plan,” “positioned,” “potential,”
“predict,” “seek,” “should,” “target,” “will,” “would,” and other
similar expressions that are predictions of or indicate future
events and future trends, or the negative of these terms or other
comparable terminology. The Company has based these forward-looking
statements largely on its current expectations, estimates,
forecasts and projections about future events and financial trends
that it believes may affect its financial condition, results of
operations, business strategy and financial needs. In light of the
significant uncertainties in these forward-looking statements, you
should not rely upon forward-looking statements as predictions of
future events. These statements are subject to risks and
uncertainties that could cause the actual results to vary
materially, including, among others, the risks inherent in drug
development such as those associated with the initiation, cost,
timing, progress and results of the Company’s current and future
research and development programs, preclinical and clinical trials,
as well as the economic, market and social disruptions due to the
ongoing COVID-19 public health crisis. For a detailed discussion of
the risk factors that could affect the Company’s actual results,
please refer to the risk factors identified in the Company’s SEC
reports, including but not limited to its Quarterly Report on Form
10-Q dated November 2, 2022. Except as required by law, the Company
undertakes no obligation to update publicly any forward-looking
statements for any reason.
Investor Relations & Media:Nicole
Keithinvestor.relations@sana.commedia@sana.com
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
Von Jul 2023 bis Jul 2024